| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly is making significant strides in product and service development, particularly through its recent $7 billion acquisition of Kelonia Therapeutics, which enhances its capabilities in oncology and genetic medicine. The approval of the GLP-1 weight loss pill, Foundayo, alongside the commitment to expand cancer treatment options, reflects a positive trend in both innovation and market positioning. However, concerns about the effectiveness of Alzheimer's drugs pose challenges in maintaining trust in their product offerings. Overall, while there are promising advancements, the company faces hurdles in addressing therapeutic efficacy in certain areas. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -1.6 is very bearish. The market sentiment at 0.6 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 1, and the negative at -0.4 on 2026-04-24. The forces of Stock Price Trend (-1.6), and Sector Price Trend (-1.4) will drive down the price. The forces of Price Level Sentiment (0.5), Option Sentiment (0.8), Market Risk Appetite (1), Valuation Sentiment (1.4), and Sentiment towards Fundamentals (2.3) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | 1%(0.4%) | 884.18 | 2.45% | 8 | -3.6% | -0.6% | -1.6 | -0.5 | 2% | 0.6 | Short | 55% | 2.3 | -1.8 |
| 2026-04-23 | 0%(0.3%) | 917.23 | 2.27% | 45 | -0.46% | -0.41% | -0.1 | 0 | 0.7% | 1.2 | Long | 55% | 2.6 | -1 |
| 2026-04-22 | 0%(0.3%) | 921.5 | 2.26% | 50 | 2.03% | -0.35% | 0.1 | 0.3 | 1.2% | 1.4 | Long | 55% | 2.7 | 5.7 |
| 2026-04-21 | 0%(0.3%) | 903.19 | 2.35% | 30 | -1.96% | -0.3% | -0.7 | -0.2 | 1.4% | 0.8 | Short | 55% | 2.5 | -1 |
| 2026-04-20 | 1%(0.3%) | 921.27 | 2.28% | 51 | -0.6% | -0.05% | -0.2 | -0.1 | 0.9% | 1.5 | Short | 55% | 2.2 | 6.2 |
| 2026-04-19 | 1%(0.1%) | -0.4 | -0.1 | 1 | 1.4 | 5.5 | ||||||||
| 2026-04-18 | 0%(0%) | -0.4 | -0.1 | 1 | 1.4 | -1 | ||||||||
| 2026-04-17 | 0%(0%) | 926.79 | 2.29% | 58 | 2.59% | -0.1% | -0.4 | 0.5 | 1.1% | 1.1 | Long | 55% | 1.7 | 4 |
| 2026-04-16 | 0%(0%) | 903.43 | 2.34% | 31 | -0.19% | -0.55% | -1.8 | -0.4 | 1.2% | 0.6 | Short | 65% | 1.1 | 5.5 |
| 2026-04-15 | 0%(0%) | 905.13 | 2.3% | 32 | -1.94% | -0.16% | -1.3 | -0.5 | 1.5% | 0.7 | Short | 55% | 1.8 | -5.5 |
| Short is the preferred trading strategy with 55% chance of being right. Weak trend sentiment and negative hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| Market News | ||
| 1 (-4) Eli Lilly Stock Falls. Foundayo Is Fighting to Catch Novo’s Wegovy Pill. Eli Lilly’s weight-loss pill appears to be falling behind oral Wegovy. Analysts say concerns are overblown. (https://www.barrons.com/) Fri. Apr 24, 2026 | ||
| 2 (-6) Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero (https://www.zerohedge.com/) Fri. Apr 24, 2026 | ||
| 3 (2) Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the day's top trending stock tickers, including prescriptions for Eli Lilly's (LLY) new GLP-1 weight-loss drug reportedly trailing the oral version of Novo Nordisk's Wegovy (NVO), JPMorgan analysts initiating coverage on Hims & Hers Health stock (HIMS), and Regeneron (REGN) offering new hearing-loss therapy plans for free. (https://finance.yahoo.com/) Fri. Apr 24, 2026 | ||
| 4 (-4) Lilly’s New Obesity Pill Off to Slow Start in Race With Novo Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up with rival Novo Nordisk A/S. (https://www.bloomberg.com/) Fri. Apr 24, 2026 | ||
| 5 (8) Lilly's obesity pill hits nearly 4000 prescriptions in second week after launch April 24 (Reuters) - Eli Lilly's newly launched oral weight loss drug was prescribed 3,707 times in the U. in the second week after its launch earlier this month, according to analysts citing IQVIA data. (https://finance.yahoo.com/) Fri. Apr 24, 2026 | ||